NO20052149L - Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein. - Google Patents

Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.

Info

Publication number
NO20052149L
NO20052149L NO20052149A NO20052149A NO20052149L NO 20052149 L NO20052149 L NO 20052149L NO 20052149 A NO20052149 A NO 20052149A NO 20052149 A NO20052149 A NO 20052149A NO 20052149 L NO20052149 L NO 20052149L
Authority
NO
Norway
Prior art keywords
hcv
sequence encoding
protein
polynucleotide sequence
virus protein
Prior art date
Application number
NO20052149A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052149D0 (no
Inventor
Paul A Hamblin
Sara Brett
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20052149D0 publication Critical patent/NO20052149D0/no
Publication of NO20052149L publication Critical patent/NO20052149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20052149A 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein. NO20052149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine
PCT/EP2003/012793 WO2004046175A1 (en) 2002-11-15 2003-11-13 Vaccine

Publications (2)

Publication Number Publication Date
NO20052149D0 NO20052149D0 (no) 2005-05-02
NO20052149L true NO20052149L (no) 2005-07-11

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052149A NO20052149L (no) 2002-11-15 2005-05-02 Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
NO20052136A NO20052136L (no) 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV).

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20052136A NO20052136L (no) 2002-11-15 2005-05-02 Vaksine mot Hepatitt C-virus (HCV).

Country Status (21)

Country Link
US (4) US20060135451A1 (enExample)
EP (2) EP1560844A1 (enExample)
JP (2) JP2006524181A (enExample)
KR (2) KR20050085009A (enExample)
CN (2) CN1738834A (enExample)
AR (1) AR041964A1 (enExample)
AU (2) AU2003288084A1 (enExample)
BR (2) BR0316291A (enExample)
CA (2) CA2504715A1 (enExample)
CO (1) CO5700833A2 (enExample)
GB (1) GB0226722D0 (enExample)
IS (2) IS7830A (enExample)
MA (2) MA27700A1 (enExample)
MX (2) MXPA05005203A (enExample)
NO (2) NO20052149L (enExample)
NZ (2) NZ539998A (enExample)
PL (2) PL376967A1 (enExample)
RU (2) RU2363492C2 (enExample)
TW (1) TW200502246A (enExample)
WO (2) WO2004046176A1 (enExample)
ZA (2) ZA200503803B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
CA2645177A1 (en) * 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
WO2008094197A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US20120100170A1 (en) * 2008-07-24 2012-04-26 Lauer Peter M Compositions and methods for the treatment of hepatitis c
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
WO2014127478A1 (en) * 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE62868B1 (en) * 1987-11-18 1995-03-08 Chiron Corp Hepatitis C virus
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
IL118364A0 (en) * 1995-05-22 1996-09-12 Bionova Corp A hepatitis C virus-derived composition methods for the preparation thereof and assays for the detection of hepatitis C virus
JP2002500502A (ja) * 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
AU774887B2 (en) * 1999-07-09 2004-07-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
EP1233982B1 (en) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113692A (ru) 2006-01-27
NZ539999A (en) 2008-03-28
CA2504654A1 (en) 2004-06-03
PL376882A1 (pl) 2006-01-09
AU2003288084A1 (en) 2004-06-15
TW200502246A (en) 2005-01-16
BR0316244A (pt) 2005-10-04
GB0226722D0 (en) 2002-12-24
CN1738834A (zh) 2006-02-22
MA27699A1 (fr) 2006-01-02
MXPA05005202A (es) 2006-01-27
AU2003288072A1 (en) 2004-06-15
BR0316291A (pt) 2005-10-11
WO2004046176A1 (en) 2004-06-03
WO2004046175A1 (en) 2004-06-03
NO20052136L (no) 2005-07-11
MA27700A1 (fr) 2006-01-02
RU2005113691A (ru) 2006-01-27
EP1560844A1 (en) 2005-08-10
CA2504715A1 (en) 2004-06-03
MXPA05005203A (es) 2006-01-27
US20060246090A1 (en) 2006-11-02
KR20050085010A (ko) 2005-08-29
US20090104231A1 (en) 2009-04-23
US20090232847A1 (en) 2009-09-17
IS7830A (is) 2005-04-28
KR20050085009A (ko) 2005-08-29
ZA200503803B (en) 2006-08-30
CO5700833A2 (es) 2006-11-30
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
JP2006524181A (ja) 2006-10-26
PL376967A1 (pl) 2006-01-23
RU2323744C2 (ru) 2008-05-10
EP1560845A1 (en) 2005-08-10
IS7831A (is) 2005-04-28
RU2363492C2 (ru) 2009-08-10
NZ539998A (en) 2008-04-30
ZA200503802B (en) 2006-08-30
AR041964A1 (es) 2005-06-01
JP2006518331A (ja) 2006-08-10
NO20052149D0 (no) 2005-05-02
CN1738833A (zh) 2006-02-22

Similar Documents

Publication Publication Date Title
NO20052149L (no) Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein.
Gawish et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF-and IFNγ-driven immunopathology
Patterson et al. Epidemiology and pathogenesis of Bolivian hemorrhagic fever
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
NO20044941L (no) Modifisert vacciniavirus Ankara til vaksinasjon av nyfodte
ATE499442T1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
Darweesh et al. Characterization of the cytopathic BVDV strains isolated from 13 mucosal disease cases arising in a cattle herd
PT1335987E (pt) Variante do virus vacina modificado ancara
CO6210761A2 (es) Vectores de virus oncoliticos de viruela
EP1554301A4 (en) TETRAVALENT DENGUE VACCINE WITH A BLACK 30 NUCLEOTIDE DELETION IN 3'-UTR OF DENGUE TYPES 1,2,3 AND 4, OR ANTIGEN CHIMERAL DENGUE VIRUSES 1,2,3 AND 4
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
Mavian et al. The genome sequence of ectromelia virus Naval and Cornell isolates from outbreaks in North America
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
Bui et al. A single amino acid substitution in the NS4B protein of Dengue virus confers enhanced virus growth and fitness in human cells in vitro through IFN-dependent host response
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
WO2021257510A3 (en) Measles virus vaccine expressing sars-cov-2 protein(s)
ATE556136T1 (de) Nichtstrukturelles hcv-fusionsprotein
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
PH12020551944A1 (en) Reverse peptide vaccine
NO20081541L (no) Ny sjo-lus vaksine
MAZHAR et al. Severe acute respiratory syndrome (Saras Covid-2): a comprehensive review
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application